Watchmaker Genomics Launches New Tech Enabling Simultaneous Detection of Methylation and Genetic Variants
TAPS+ chemistry preserves DNA integrity in challenging samples including FFPE tissue and circulating tumor DNA.
TAPS+ chemistry preserves DNA integrity in challenging samples including FFPE tissue and circulating tumor DNA.
Roche's Elecsys pTau181 assay gives clinical labs a key role in the initial evaluation of cognitive decline, helping to rule out amyloid pathology earlier in the diagnostic process.
UCLA Health researchers find cell-free DNA combined with machine learning can distinguish ALS from other neurological conditions.
PATHFINDER 2 study results indicate more than half of cancers detected by Galleri test were found in early stages, with three-quarters having no current screening options.
A field-deployable test demonstrates high sensitivity in identifying low-level infections that traditional methods miss, potentially supporting elimination efforts.
Researchers urge clinicians to integrate lipid management into prenatal care to mitigate elevated obstetric complications and cardiovascular risks.
From rising demand for comprehensive IgE profiles to the emergence of molecular allergen diagnostics, laboratories are central to how clinicians prepare for and manage September’s asthma spike.
Study of more than 13,000 individuals demonstrates improved precision for emergency department triage and patient outcomes.
The Elecsys pTau181 test measures phosphorylated Tau 181 protein to help rule out Alzheimer's-related amyloid pathology in patients 55 and older.
The automated system uses ion exchange HPLC technology to deliver A1c results while detecting common hemoglobin variants.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
TriVerity system demonstrated high sensitivity and specificity across more than 1,200 patients in pivotal SEPSIS-SHIELD trial.